Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 10, 2011, Pages 1193-1201

  Hollebecque, A ^a   Cattan, S ^a   Romano, O ^a   Sergent, G ^a   Mourad, A ^a   Louvet, A ^a   Dharancy, S ^a   Boleslawski, E ^a   Truant, S ^a   Pruvot, F R ^a   Hebbar, M ^a   Ernst, O ^a   Mathurin, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; AGED; ALOPECIA; ANUS FISTULA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASE CONTROL STUDY; CHILD PUGH SCORE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; LIVER CELL CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80055017402     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04860.x     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
3. Llovet JM, Brà C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
4. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Available at:. Accessed September 17, 2011.
5. Chaparro M, Gonzales Moreno L, Trapero-Marugan M, et al. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008; 28: 1269-77.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
7. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
8. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7. (Pubitemid 29023987)
9. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300. (Pubitemid 46630787)
10. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 391-8.
11. Di Maio M, Daniele B, Perrone F,. Targeted therapies: role of sorafenib in HCC patients with compromized liver function. Nat Rev Clin Oncol 2009; 6: 505-6.
12. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
14. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M,. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract 2010; 64: 1034-41.
15. Bronowicki JP, Marrero J, Lim H, et al. Sorafenib treatment and safety profile in Child-Pugh B patients characterized in first interim results of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). Eastern and Western Experiences (IMHCC 2011), 7th international meeting, 14-15 January 2011, Paris, France.
16. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-6.
17. Wörns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-95.
18. Ozenne V, Paradis V, Pernot S, et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106-10.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
20. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
21. Shao Y-Y, Lin Z-Z, Hsu C, Shen Y-C, Hsu C-H, Cheng A-L,. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-6.
22. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9: 208.
23. Maksimovic O, Schraml C, Hartmann JT, et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. Am J Roentgenol 2010; 194: 5-14.
24. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-23.
25. Chan SL, Mo FKF, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 446-52.
26. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
27. Levy G, Cattan S, Sergent G, et al. Assessment of response to sorafenib in hepatocellular carcinoma: prognostic value of tumoral density and arterial enhancement measurements in target lesions. Abstract accepted at the EASL International Liver Congress 2011, 30 March-3 April 2011, Berlin, Germany.
28. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM,. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.